Genmab A/S (GMAB) Competitors

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Does the media refer more to GMAB or TAK?

In the previous week, Genmab A/S had 2 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 4 mentions for Genmab A/S and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.04 beat Genmab A/S's score of 0.34 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, GMAB or TAK?

Genmab A/S has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.

Is GMAB or TAK more profitable?

Genmab A/S has a net margin of 36.30% compared to Takeda Pharmaceutical's net margin of 4.53%. Genmab A/S's return on equity of 16.78% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	36.30%	16.78%	13.79%
Takeda Pharmaceutical	4.53%	9.39%	4.53%

Does the MarketBeat Community prefer GMAB or TAK?

Genmab A/S received 66 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 62.78% of users gave Genmab A/S an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 167 62.78%	Underperform Votes 99 37.22%
Takeda Pharmaceutical	Outperform Votes 101 57.06%	Underperform Votes 76 42.94%

Do analysts recommend GMAB or TAK?

Genmab A/S currently has a consensus price target of $39.17, indicating a potential upside of 73.07%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders believe in GMAB or TAK?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has preferable earnings and valuation, GMAB or TAK?

Genmab A/S has higher earnings, but lower revenue than Takeda Pharmaceutical. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	4.66	$1.14B	$1.76	12.86
Takeda Pharmaceutical	$4.58T	0.01	$994.06M	$0.22	69.02

Summary

Genmab A/S beats Takeda Pharmaceutical on 14 of the 19 factors compared between the two stocks.